Biotech Values

[nuere]

OXGN – The market response reflected the fact that it was a favourable dilution but, as stockbettor said, it also indicated that a partnership is not going to happen next week.. Since "the market" is very short-sighted not enough investor/traders found it worthwhile jumping on the "oxgn train" at this moment.
I expect to see a gradual accumulation of oxgn by those who understand the huge potential of the VDA technology and knows that Oxigene is close to signing a good partnering deal.